The Rheumatologist
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
  • Technology
    • Electronic Health Records
    • Apps
    • Information Technology
  • Resources
    • Issue Archives
    • Events
    • Multimedia
      • Audio
      • Video
    • From the College
    • American College of Rheumatology
    • Rheumatology Research Foundation
    • Arthritis & Rheumatology
    • Arthritis Care & Research
    • Treatment Guidelines
    • Research Reviews
    • Annual Meeting
      • Abstracts
      • Meeting Reports
    • Rheumatology Image Bank
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Four-Week Methotrexate Break Improves Flu Shot Response in RA Patients

Four-Week Methotrexate Break Improves Flu Shot Response in RA Patients

May 17, 2017 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Temporarily withholding methotrexate (MTX) can improve the efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis (RA), according to a new randomized clinical trial.

You Might Also Like
  • Higher Tocilizumab Dose Plus Methotrexate Best for Early RA
  • Triple Therapy with Methotrexate Effective, Cheaper in RA
  • 2014 ACR/ARHP Annual Meeting: Methotrexate Use in Patients with RA

Response was strongest in patients who discontinued MTX for two weeks before and two weeks after receiving the flu shot, Dr. Eun Bong Lee of Seoul National University College of Medicine in Korea and colleagues reported online May 3 in Annals of the Rheumatic Diseases.

MTX impairs response to the pneumococcal and seasonal influenza vaccines, particularly to “presumably novel antigens such as new pandemic H1N1 influenza antigen,” Dr. Lee and colleagues note.

To investigate whether halting MTX for four weeks around the time of immunization could improve response, the researchers randomly assigned 199 patients to either continue taking MTX or to stop MTX for four weeks before vaccination, for two weeks before and two weeks after, or for four weeks after immunization.

Satisfactory responses to all three antigens in the vaccine (i.e., at least a 4-fold increase in hemaglutination inhibition antibody titer) were seen in 51% of patients who stopped MTX for two weeks before and two weeks after, compared to 31.5% of those who didn’t stop the drug at all (p=0.044).

MTX suspension for four weeks before vaccination did not yield better results than continuing the drug without stopping, whereas suspending it for four weeks afterward showed a trend toward better results compared to not stopping at all.

Anti-H3N2 antibodies increased 12.2-fold in the before-and-after group and 10-fold for those who stopped MTX for four weeks after immunization, compared to 5.9-fold in patients who continued on MTX throughout. Anti-B-Yamagata antibody fold increases in those groups, respectively, were 4.7, 6.1, and 2.9.

Flares occurred in 24% to 39% of patients, with no significant difference between the groups. Almost all patients who had flares recovered when they began taking MTX again.

“Further studies that determine the optimal duration of MTX discontinuation that improves vaccine efficacy while avoiding RA flares are warranted,” the researchers write.

“These data suggest that the effect of MTX on immune cells is actually immediate, whereas the disease-modifying effects of MTX . . . may take significantly longer to evolve,” Dr. Lee and colleagues state. “The fact that discontinuing MTX improves immune responses to vaccines also supports the clinical practice that MTX be discontinued during acute (life-threatening) infections.”

Future research should investigate whether discontinuing MTX reduces the incidence of influenza or changes its disease course, they conclude.

Pages: 1 2 Single Page

Filed Under: Drug Updates, Practice Management, Rheumatoid Arthritis Tagged With: discontinued MTX, Methotrexate, Rheumatoid arthritis, seasonal influenza vaccination

You Might Also Like:
  • Higher Tocilizumab Dose Plus Methotrexate Best for Early RA
  • Triple Therapy with Methotrexate Effective, Cheaper in RA
  • 2014 ACR/ARHP Annual Meeting: Methotrexate Use in Patients with RA
  • Heart Rate Variability to Predict Treatment Response in Patients with RA

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR/ARP Meeting Abstracts

Browse and search abstracts from the ACR/ARP Annual Meetings going back to 2012.

Visit the ACR/ARP Meeting Abstracts site »

ACR/ARP Annual Meeting

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Annual Meeting site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2019 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.